Quality of Life in Lung Cancer: The Validity and Cross-Cultural Applicability of the Functional Assessment of Cancer Therapy–Lung Scale

2005 ◽  
Vol 19 (2) ◽  
pp. 389-420 ◽  
Author(s):  
Zeeshan Butt ◽  
Kimberly Webster ◽  
Amy R. Eisenstein ◽  
Jennifer Beaumont ◽  
David Eton ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Cross Cultural

Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 18140-18140
Author(s):  
V. Alberola ◽  
O. Gallego ◽  
G. López-Vivanco ◽  
C. Mesía ◽  
J. Oramas ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Objective Response ◽  
Well Being ◽  
End Point ◽  
Trial Outcome Index ◽  
Outcome Index

18140 Background: Erlotinib is an EGFR TKI that is effective in the treatment of advanced NSCLC, in terms of longer survival, better quality of life and delayed symptom progression.We present here the outcome of a group of p from the TargeT study, whose QoL was assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire and the Lung Cancer Subscale (LCS). Methods: TargeT study was a multicenter, single-arm phase II study evaluating efficacy, safety, and tolerability of erlotinib (150 m/day) in p with stage IIIB or IV NSCLC, in 1st, 2nd and 3rd line treatment. Primary end-point was time to progression. QoL was a secondary end point as assessed monthly by the Functional Assessment of Cancer Therapy-Lung questionnaire (FACT- L) and its Lung Cancer Subscale. Physical and functional aspects of the QoL were measured by the Trial Outcome Index (TOI), which is the sum of the physical well being, functional well-being and LCS scores from the FACT-L questionnaire. Results: Data from 91 pts were available. QoL analysis showed that 53% of the p (95% IC 37–58%) had improvement in FACT-L or TOI. Similarly, 45% (95% IC35–56%) of improved their symptoms from baseline. Improvement was observed for each individual LCS item and specifically in the pulmonary items. In symptomatic p, shortened of breath was 17,6% at baseline vs 2.2% after treatment (p<0.001) and cough was 24.7% vs 8.8 % (p<0.001) after treatment. Those improvements in symptoms were rapid and, 73% of the patients who improved showed that recovery in the first cycle of treatment. In terms of association between efficacy of erlotinib and QoL, there is a statistically significative relationship between objective response and improvement in TOI or FACT-L (p<0.02). Conclusions: This QoL analysis confirms that erlotinib improves both symptoms and functional aspect of patients with NSCLC. The improvement in QoL is related with objective response. No significant financial relationships to disclose.

Psychometric evaluation of the Taiwanese version of the functional assessment of cancer therapy: a questionnaire for patients with lung cancer

2018 ◽  
Vol 31 (7) ◽  
pp. 513-518
Author(s):  
Wen-Pei Chang ◽  
Yen-Kuang Lin ◽  
Chia-Chin Lin
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Longitudinal Research ◽  
Characteristic Curve ◽  
Reliability And Validity ◽  
Psychometric Evaluation ◽  
Diagnosis Of Lung Cancer

Abstract Objective The Functional Assessment of Cancer Therapy-Lung (FACT-L) consists of the Functional Assessment of Cancer Therapy-General (FACT-G) and the Lung Cancer Subscale. The FACT-L is commonly used to measure quality of life in patients with lung cancer. This study evaluated the reliability and validity of the FACT-L in examining patients with lung cancer in Taiwan. Design This was a methodology study. Setting Patients with lung cancer at a regional hospital in Northern Taiwan. Participants Patients who had received an early diagnosis of lung cancer between 2013 and 2015 were recruited as respondents. Intervention(s) None. Main outcome measure(s) To verify the reliability and validity of the Taiwanese version of the FACT-L. Results A total of 104 patients who had received an initial diagnosis of lung cancer were recruited. The overall internal consistency of the FACT-L, as assessed using Cronbach’s α, was 0.82. Among the patients, 64 had a test–retest reliability (r) of 0.45 (P < 0.001) at 6 weeks after treatment. Moreover, longitudinal research indicated that the FACT-L detected score differences before and after treatment in these patients (Cohen’s d = −0.26). The Taiwanese version of the FACT-L considers 2-year survival as the gold standard, and the optimal combination of sensitivity and specificity was obtained when the receiver operating characteristic curve revealed cutoff points of 80 and 68 for the FACT-L and FACT-G, respectively. Conclusions The Taiwanese version of the FACT-L can be widely applied to assess the quality of life of patients with lung cancer.

scholarly journals Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

2021 ◽  
Vol 18 (11) ◽  
pp. 5677
Author(s):  
Hsing-Wei Hung ◽  
Chien-Ying Liu ◽  
Hsiu-Fang Chen ◽  
Chun-Chu Chang ◽  
Shu-Ching Chen
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Peripheral Neuropathy ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Motor Impairment ◽  
Depression Scale ◽  
Advanced Lung Cancer ◽  
Platinum Based Chemotherapy

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy. This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN (European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy–induced peripheral neuropathy 20), anxiety (Hospital Anxiety and Depression Scale Depression Scale [HADS]), depression (HADS), CIPN-related QoL (Functional Assessment of Cancer Therapy /Gynecologic Oncology Group-Neurotoxicity subscale [FACT/GOG–Ntx]), and general QoL (Functional Assessment of Cancer Therapy–General Input [FACT-G]). Of 93 patients with advanced LC, 53.8% reported CIPN–sensory impairment and 47.3% reported CIPN–motor impairment. The most common CIPN symptoms were difficulty getting or maintaining an erection (only for men > 65 years) and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL (FACT/GOG–Ntx) was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL (FACT-G) was associated with a higher level of depression, a higher level of anxiety, and receipt of more chemotherapy cycles. More than half of LC patients report impairment related to CIPN, calling for holistic treatment to improve QoL.

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Urology ◽  
1997 ◽  
Vol 50 (6) ◽  
pp. 920-928 ◽  
Author(s):  
Peg Esper ◽  
Fei Mo ◽  
Gerald Chodak ◽  
Michael Sinner ◽  
David Cella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Therapy ◽  
Functional Assessment

The functional assessment of cancer therapy–BRM (FACT–BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers

2004 ◽  
Vol 13 (1) ◽  
pp. 137-154 ◽  
Author(s):  
J. Bacik ◽  
M. Mazumdar ◽  
B.A. Murphy ◽  
D.L. Fairclough ◽  
S. Eremenco ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Biologic Response

scholarly journals Validation of the 7‐item Functional Assessment of Cancer Therapy‐General (FACT‐G7) as a short measure of quality of life in patients with advanced cancer

Cancer ◽  
2020 ◽  
Vol 126 (16) ◽  
pp. 3750-3757
Author(s):  
Kenneth Mah ◽  
Nadia Swami ◽  
Lisa W. Le ◽  
Ronald Chow ◽  
Breffni L. Hannon ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Therapy ◽  
Advanced Cancer ◽  
Functional Assessment ◽  
General Fact
Sign in / Sign up

Export Citation Format

Share Document